Author

Joshua D’Rozario

University of CologneORCID 0000-0002-3380-4801Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

Julie GeorgeiD· 2 shared Roman Kurt ThomasiD· 2 shared Agnieszka Rumińska· 1 shared Ahmad Al AlwashiD· 1 shared Alessandra GarganoiD· 1 shared Alexander QuaasiD· 1 shared Angelika Beate RiemeriD· 1 shared Anna SchöllhorniD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Julie GeorgeORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Mapping the immune landscape in small cell lung cancer unveils a distinct tumor-reactive CD8+ T cell molecular signature

Krutika Khinvasara, Elif Diken, Jennifer V. Gerbracht, Enes Huduti, Joshua D’Rozario, Tana Omokoko, Sebastian Newrzela, Özlem Akilli‐Öztürk, Franziska Lang, Barbara Schrörs, Katja Hoepker, Eliana Stanganello, Maik Schork, Alessandra Gargano, Ahmad Al Alwash, , LAURA D. KOLB

This study identifies a CD8+ T cell molecular signature specific to small cell lung cancer, showing its prognostic value and potential for immunotherapy.

bioRxiv · Jul 3, 2026 · PreprintImmunology

A targetable dependency on nonsense-mediated decay for proteostasis and immune control in small cell lung cancer

Lucia Torres Fernández, Volker Boehm, Joel Kaufmann, Agnieszka Rumińska, Jonas Philipp Becker, María García Márquez, Beaunelle de Bruijn, Christian Müller, Nazanin Alavinejad, Laura Lovric, Johanna I. Bihler, Kian R. Weihrauch, Laura Kaiser, Marcel Schmiel, Lukas Maas, , Julie George

This study identifies NMD inhibition as a therapeutic strategy for SCLC by enhancing immunogenicity and improving immunotherapy efficacy through increased neoantigen presentation.

bioRxiv · Apr 2, 2026 · PreprintCancer Biology